Ipsen Pharma

The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors (2023) Pavel ME, Dromain C, Ronot M, Schaefer N, Mandair D, Gueguen D, Elvira D, et al. Journal article Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors (2023) Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al. Journal article Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. (2023) Bang P, Polak M, Bossowski A, Maghnie M, Argente J, Ramon-Krauel M, Sert C, et al. Journal article Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution Pathway to assess severe primary IGF-1 deficiency diagnosis in a real-life setting: data from the Global Increlex (R) Registry (2022) Bang P, Polak M, Bossowski A, De Schepper J, Sert C, Perrot V, Wölfle J Conference contribution Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex® Growth Forum Database Registry (2022) Bang P, Polak M, Perrot V, Sert C, Shaikh H, Wölfle J Journal article Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results (2021) Pavel ME, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, et al. Journal article Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST (2021) Srirajaskanthan R, Pavel ME, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO Journal article Assessment of genetic defects, baseline characteristics and adverse events reported in the Increlex (R) registry (2021) Polak M, Bang P, Perrot V, Sert C, Storr HL, Wölfle J Conference contribution